Kypri Kypros, Austin Emma, Jackson Melissa, Wright Kirsten, Shui Amanda, Li Andrew, Sathasivam Vinogi, Bonevski Billie, Dunlop Adrian J
Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia.
School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia.
Drug Alcohol Rev. 2025 Jan;44(1):254-266. doi: 10.1111/dar.13953. Epub 2024 Oct 4.
Most patients receiving opioid agonist treatment (OAT) smoke tobacco. Approved cessation interventions are less effective in this group than the wider population. We investigated how people on OAT experience nicotine vaping to quit smoking.
Patients on OAT randomised to the vaping arm of a smoking cessation trial were invited to participate in structured interviews incorporating broad pre-determined themes. A qualitative descriptive approach employing template analysis was used. Four authors coded transcripts, discussed discrepancies, modified the template using both inductive and deductive approaches. Authors made explicit their starting orientations and independent authors sought disconfirmatory data in a subsequent round of analysis.
Four women and eight men (median age 44 years) participated, including four who identified as Aboriginal. Participants reported vaping as cheaper, more acceptable and less stigmatising than smoking but expressed concerns about ongoing accessibility due to the Australian prescription access model. Some found it technically challenging at first, but not more so than standard nicotine replacement therapies. Participants gave accounts of craving and withdrawal experiences, including supplementary use of nicotine patches, and compulsions to vape frequently and intensely, potentially indicating need for higher nicotine dosage. Participants generally reported that vaping helped them quit smoking, though some worried about swapping nicotine addictions. Others were glad to be using a lower-risk alternative.
This group reported varied experiences of nicotine vaping but were mainly optimistic that it could help them and others quit smoking. This was despite initial nicotine cravings and concerns about remaining addicted long-term.
大多数接受阿片类激动剂治疗（OAT）的患者吸烟。已获批的戒烟干预措施在该群体中的效果不如在更广泛人群中有效。我们调查了接受OAT治疗的人使用尼古丁电子烟戒烟的体验。
被随机分配到一项戒烟试验电子烟组的接受OAT治疗的患者受邀参加包含广泛预定主题的结构化访谈。采用了运用模板分析的定性描述方法。四位作者对访谈记录进行编码，讨论差异，使用归纳法和演绎法修改模板。作者明确了他们的初始取向，独立作者在后续分析中寻找反证数据。
四名女性和八名男性（中位年龄44岁）参与其中，包括四名自认为是原住民的人。参与者报告称，与吸烟相比，吸电子烟更便宜、更容易接受且耻辱感更低，但由于澳大利亚的处方获取模式，他们对电子烟的持续可及性表示担忧。一些人起初觉得在技术上有挑战性，但并不比标准尼古丁替代疗法更具挑战性。参与者讲述了渴望和戒断经历，包括补充使用尼古丁贴片，以及频繁且强烈地想要吸电子烟的冲动，这可能表明需要更高的尼古丁剂量。参与者普遍报告称吸电子烟帮助他们戒了烟，不过有些人担心会从一种尼古丁成瘾转换到另一种。其他人很高兴能使用风险较低的替代方法。
该群体报告了吸尼古丁电子烟的不同体验，但总体上对其能帮助他们及他人戒烟持乐观态度。尽管最初有尼古丁渴望以及对长期保持成瘾的担忧，但情况依然如此。
